Vanda Pharmaceuticals Inc.
NASDAQ:VNDABiotechnology
-$0.20 today
- Market cap
- $226.76M
- Beta
- 0.60
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$4.03
Volume 0.95M
Average 1.29M
VNDA EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Vanda Pharmaceuticals Inc.NASDAQ: VNDA
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$44.9M, compared with -$31.12M a year earlier. Trailing-twelve-month EBITDA was -$136.24M.
Context
- EBITDA amounted to 58.6% of revenue in FY2025, up 51.2 pp from a year earlier.
- EBITDA increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of -$139.07M (-9.7%) for the fiscal year ending Dec 2026, a step up from the -756.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$44.9M-39.7% QoQ
- Last fiscal yearDec 2025
- -$126.73M-756.9% YoY
- LTMMar 2026
- -$136.24M-213.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -44.3% | +4.1% | +48.4 pp |
| 1 year | -756.9% | -9.7% | +747.2 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (126.73M) USD
- Year-over-year change
- -756.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (126.73M) | -756.9% |
| FY2024 | 2024-12-31 | (14.79M) | -258.2% |
| FY2023 | 2023-12-31 | 9.35M | -33.4% |
| FY2022 | 2022-12-31 | 14.03M | -69.0% |
| FY2021 | 2021-12-31 | 45.21M | — |
EBITDA vs competitors
How VNDA compares with its peers on the latest reported figures
- VNDA's LTM Mar 2026 EBITDA of -$136.24M is the 8th highest of the 11 companies compared; the peer median is -$73.65M.
- Its year-over-year change of -213.5% is the 10th highest of 11, against a peer median of -9.1%.
- EBITDA amounts to 62.6% of revenue for VNDA, versus a peer median of 1590.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $893.33M | +1767.7% | — | — | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | -$46.14M | +19.2% | — | — |
| LTM Mar 2026 | -$50.86M | -14.6% | — | — | |
| LTM Mar 2026 | -$58.85M | +7.0% | — | — | |
| LTM Mar 2026 | -$67.53M | -3.7% | — | 148.9% | |
| LTM Mar 2026 | -$79.77M | -33.1% | — | 3956.7% | |
| LTM Mar 2026 | -$112.54M | -37.5% | — | 308.4% | |
| LTM Mar 2026 | -$136.24M | -213.5% | — | 62.6% | |
| LTM Mar 2026 | -$160.41M | +32.7% | — | — | |
| LTM Mar 2026 | -$164.87M | -697.5% | — | 2873.3% | |
| LTM Mar 2026 | -$179.89M | -30.1% | — | — | |
| Peer median (excluding VNDA) | -$73.65M | -9.1% | — | 1590.9% | |
Competitors are the stored peer set for VNDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 268.68M | 254.38M | 192.64M | 198.77M | 216.11M |
| Cost of Revenue | 25.63M | 24.28M | 14.8M | 11.31M | 13.04M |
| Gross Profit | 243.05M | 230.1M | 177.84M | 187.46M | 203.06M |
| Gross Margin | 90.5% | 90.5% | 92.3% | 94.3% | 94.0% |
| Research & Development | 75.36M | 85.77M | 76.82M | 74.43M | 109.27M |
| Selling, General & Admin | 124.05M | 136.49M | 112.88M | 146.41M | 237.95M |
| Operating Expenses | 200.89M | 223.77M | 191.8M | 228.12M | 354.23M |
| Depreciation & Amortization | 2.84M | 2.73M | 3.01M | 8.13M | 11.92M |
| EBITDA | 45.21M | 14.03M | 9.35M | (14.79M) | (126.73M) |
| EBITDA Margin | 16.8% | 5.5% | 4.9% | -7.4% | -58.6% |
| Operating Income | 42.17M | 6.33M | (13.95M) | (40.66M) | (151.17M) |
| Operating Margin | 15.7% | 2.5% | -7.2% | -20.5% | -70.0% |
| Interest Income | 199K | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 199K | 4.97M | 20.29M | 17.74M | 12.52M |
| Income Before Tax | 42.36M | 11.3M | 6.34M | (22.92M) | (138.65M) |
| Pre-Tax Margin | 15.8% | 4.4% | 3.3% | -11.5% | -64.2% |
| Income Tax Expense | 9.21M | 5.03M | 3.83M | (4.02M) | 81.83M |
| Net Income | 33.15M | 6.28M | 2.51M | (18.9M) | (220.47M) |
| Net Margin | 12.3% | 2.5% | 1.3% | -9.5% | -102.0% |
| EPS (Basic) | 0.60 | 0.11 | 0.04 | (0.32) | (3.74) |
| EPS (Diluted) | 0.58 | 0.11 | 0.04 | (0.32) | (3.74) |
| Weighted Avg Shares | 55.55M | 56.46M | 57.38M | 58.15M | 58.93M |
| Weighted Avg Shares (Diluted) | 56.92M | 56.98M | 57.56M | 58.15M | 58.93M |
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
Intrinsic Alpha fair value
Locked
Current Price
$3.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.